66 related articles for article (PubMed ID: 18981857)
1. Preferential expression of chemokine receptor CXCR4 by highly malignant human gliomas and its association with poor patient survival.
Ehtesham M; Stevenson CB; Thompson RC
Neurosurgery; 2008 Oct; 63(4):E820; author reply E820. PubMed ID: 18981857
[No Abstract] [Full Text] [Related]
2. Preferential expression of chemokine receptor CXCR4 by highly malignant human gliomas and its association with poor patient survival.
Bian XW; Yang SX; Chen JH; Ping YF; Zhou XD; Wang QL; Jiang XF; Gong W; Xiao HL; Du LL; Chen ZQ; Zhao W; Shi JQ; Wang JM
Neurosurgery; 2007 Sep; 61(3):570-8; discussion 578-9. PubMed ID: 17881971
[TBL] [Abstract][Full Text] [Related]
3. Expression of CXCL12 and its receptor CXCR4 in esophageal squamous cell carcinoma.
Sasaki K; Natsugoe S; Ishigami S; Matsumoto M; Okumura H; Setoyama T; Uchikado Y; Kita Y; Tamotsu K; Hanazono K; Owaki T; Aikou T
Oncol Rep; 2009 Jan; 21(1):65-71. PubMed ID: 19082444
[TBL] [Abstract][Full Text] [Related]
4. Expression pattern and clinical prognostic relevance of bone morphogenetic protein-2 in human gliomas.
Liu C; Tian G; Tu Y; Fu J; Lan C; Wu N
Jpn J Clin Oncol; 2009 Oct; 39(10):625-31. PubMed ID: 19797419
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of CXCR-4 expression in oral squamous cell carcinoma.
Lee JI; Jin BH; Kim MA; Yoon HJ; Hong SP; Hong SD
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 May; 107(5):678-84. PubMed ID: 19272813
[TBL] [Abstract][Full Text] [Related]
6. [CXCR4 combined with P504S or P63 in differential diagnosis of benign and malignant prostatic diseases].
Qu F; Xing YF; Xiao YJ; Xiao CG; Guo HQ
Zhonghua Nan Ke Xue; 2008 Dec; 14(12):1059-62. PubMed ID: 19157222
[TBL] [Abstract][Full Text] [Related]
7. [Influence of activation of human glioma cell CXCR4 receptor on the expression of vascular endothelial growth factor].
Yang SX; Bian XW; Jiang XF; Chen JH; Wang QL; Wang JM
Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(12):845-7. PubMed ID: 15949405
[No Abstract] [Full Text] [Related]
8. Survival benefit of boron neutron capture therapy for recurrent malignant gliomas.
Miyatake S; Kawabata S; Yokoyama K; Kuroiwa T; Michiue H; Sakurai Y; Kumada H; Suzuki M; Maruhashi A; Kirihata M; Onoc K
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S22-4. PubMed ID: 19394240
[TBL] [Abstract][Full Text] [Related]
9. Glioma vascularity correlates with reduced patient survival and increased malignancy.
Russell SM; Elliott R; Forshaw D; Golfinos JG; Nelson PK; Kelly PJ
Surg Neurol; 2009 Sep; 72(3):242-6; discussion 246-7. PubMed ID: 19329156
[TBL] [Abstract][Full Text] [Related]
10. CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival.
Wagner PL; Hyjek E; Vazquez MF; Meherally D; Liu YF; Chadwick PA; Rengifo T; Sica GL; Port JL; Lee PC; Paul S; Altorki NK; Saqi A
J Thorac Cardiovasc Surg; 2009 Mar; 137(3):615-21. PubMed ID: 19258077
[TBL] [Abstract][Full Text] [Related]
11. Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis.
Shen A; Wang Y; Zhao Y; Zou L; Sun L; Cheng C
Neurosurgery; 2009 Jul; 65(1):153-9; discussion 159-60. PubMed ID: 19574837
[TBL] [Abstract][Full Text] [Related]
12. The survival impact of postoperative infection in patients with glioblastoma multiforme.
Bohman LE; Gallardo J; Hankinson TC; Waziri AE; Mandigo CE; McKhann GM; Sisti MB; Canoll P; Bruce JN
Neurosurgery; 2009 May; 64(5):828-34; discussion 834-5. PubMed ID: 19404146
[TBL] [Abstract][Full Text] [Related]
13. Beyond grade: molecular pathology of malignant gliomas.
Sulman EP; Guerrero M; Aldape K
Semin Radiat Oncol; 2009 Jul; 19(3):142-9. PubMed ID: 19464628
[TBL] [Abstract][Full Text] [Related]
14. Brainstem gliomas--retrospective analysis of 86 patients.
Ueoka DI; Nogueira J; Campos JC; Maranhão Filho P; Ferman S; Lima MA
J Neurol Sci; 2009 Jun; 281(1-2):20-3. PubMed ID: 19345380
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of systemic radionuclide therapy with p-131I-iodo-L-phenylalanine combined with external beam photon irradiation in treating malignant gliomas.
Samnick S; Romeike BF; Lehmann T; Israel I; Rübe C; Mautes A; Reiners C; Kirsch CM
J Nucl Med; 2009 Dec; 50(12):2025-32. PubMed ID: 19910430
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive markers in glioma and other neuroepithelial tumors.
Rivera AL; Pelloski CE; Sulman E; Aldape K
Curr Probl Cancer; 2008; 32(3):97-123. PubMed ID: 18501774
[No Abstract] [Full Text] [Related]
17. COX-2 expression in malignant melanoma: a novel prognostic marker?
Becker MR; Siegelin MD; Rompel R; Enk AH; Gaiser T
Melanoma Res; 2009 Feb; 19(1):8-16. PubMed ID: 19430402
[TBL] [Abstract][Full Text] [Related]
18. STAT3 expression in gastric cancer indicates a poor prognosis.
Kim DY; Cha ST; Ahn DH; Kang HY; Kwon CI; Ko KH; Hwang SG; Park PW; Rim KS; Hong SP
J Gastroenterol Hepatol; 2009 Apr; 24(4):646-51. PubMed ID: 19175826
[TBL] [Abstract][Full Text] [Related]
19. Aryl hydrocarbon receptor inhibition downregulates the TGF-beta/Smad pathway in human glioblastoma cells.
Gramatzki D; Pantazis G; Schittenhelm J; Tabatabai G; Köhle C; Wick W; Schwarz M; Weller M; Tritschler I
Oncogene; 2009 Jul; 28(28):2593-605. PubMed ID: 19465936
[TBL] [Abstract][Full Text] [Related]
20. pS2 (TFF1) expression in prostate carcinoma: correlation with steroid receptor status.
Abdou AG; Aiad HA; Sultan SM
APMIS; 2008 Nov; 116(11):961-71. PubMed ID: 19132993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
